The biopharmaceutics risk assessment roadmap (bioram): building in clinical relevance for the patient benefit
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: SELEN, Arzu (Maryland, United States of America)
Significant advances are taking place in expanding biopharmaceutics methods and tools into highly predictive and novel technologies for optimizing drug products and enhancing the patient benefit. The value of biopharmaceutics in drug product characterization and optimization has been widely published since early.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.